Win a $28,000 Color Bar Makeover With Vish and Minerva
Beauty Launchpad
JULY 29, 2024
Two major influencers in the world of salon management have joined forces to elevate the in-salon experience with a new $28,000 color bar makeover up for grabs.
Mon.Jul 29, 2024
98 
Lori Crete’s SpaStar® Launches Pro Portal
Spa Industry Association
JULY 29, 2024
Online support and tools to successfully market iconic Get Ready Wrap® focus on increasing revenues and guest satisfaction. Palm Desert, Calif (July 16, 2024) Beauty business expert Lori Crete is pleased to introduce the new SpaStar® Pro Portal with resources and tools to support spa owners, spa directors, and estheticians. The portal includes brand elements, sales scripts, shelf-talkers, video demonstrations, and articles on best practices, aimed at successfully marketing SpaStar’s iconic Get R
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Have Recent Innovations Increased Demand for Body Sculpting Treatments? [Survey]
MedEsthetics
JULY 29, 2024
Have recent aesthetic treatment innovations led to increased patient demand for body sculpting?
MULTI-GRAMMY AWARD-WINNING PIANIST AND COMPOSER PETER KATER TO HEADLINE WORLD’S LARGEST SALT THERAPY & WELLNESS EVENT
Spa Industry Association
JULY 29, 2024
LAKE BUENA VISTA, FL – July 18, 2024 – The Salt Therapy Association (STA) is thrilled to announce that Myndstream, a leading health and wellness music provider, will bring the highly talented Peter Kater , a multi-Grammy award-winning and multi-Platinum-selling pianist, composer, producer, and breathwork practitioner, as a featured speaker to STAconLIVE 2024.
We are Biologic Coordinators of Dermatology (BCoD)
Dermatology Times
JULY 29, 2024
Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.
What Will the FDA Approval of Sun Pharma’s Alopecia Drug Mean for Patients?
The Dermatology Digest
JULY 29, 2024
Benjamin Ungar, MD, the Director of the Alopecia Center of Excellence at Mount Sinai in New York City, discusses what the U.S. Food and Drug Administration approval of Sun Pharma’s LEQSELVI (deuruxolitinib) will mean for adults with severe alopecia areata. The post What Will the FDA Approval of Sun Pharma’s Alopecia Drug Mean for Patients? appeared first on The Dermatology Digest.
Sign up to get articles personalized to your interests!
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
More Trending
Best Ingredients to Pair and Avoid with Retinol
US Dermatologt Partners
JULY 29, 2024
Retinol is one of the most beneficial skincare ingredients available. Naturally derived from vitamin A, this skincare powerhouse offers acne-fighting, anti-aging, complexion-brightening results that are incomparable to other ingredients. All of this comes with one big caveat – you have to use it correctly. While retinol transforms skin’s health and appearance, it may also lead to irritation, inflammation, skin redness, and a range of other side effects when used improperly or in combination with
Pediatric Dermatology Highlights in July
Dermatology Times
JULY 29, 2024
From ER visits for dystrophic epidermolysis bullosa to rates of axillary hyperhidrosis, catch up on top pediatric insights from July.
The Lip Flip Trend
Aesthetic Advancements Institute (AAI)
JULY 29, 2024
Chances are, if you’re an active injector on social media, you’ve heard of the neurotoxins Lip Flip trend. While it’s actually been around for a long time, it provides a great opportunity for marketing to your patients who are just now hearing about it! What is a lip flip? A lip flip with neurotoxins is a subtle, but transformative procedure that enhances lip appearance without the need for dermal fillers.
Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%
Dermatology Times
JULY 29, 2024
Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.
Enrollment Complete in Phase 3 Study of Brepocitinib in DM
The Dermatology Digest
JULY 29, 2024
Enrollment in Phase 3 VALOR study evaluating brepocitinib in dermatomyositis is now complete, according to Priovant Therapeutics. Data are anticipated in the second half of calendar year 2025, with a potential New Drug Application (NDA) submission to follow. Brepocitinib is a dual selective inhibitor of oral tyrosine kinase 2 (TYK2) inhibitor and J anus kinase (JAK1) administered orally once daily.
Australian Analysis Calls for Diversity in Dermatological Research
Dermatology Times
JULY 29, 2024
Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.
PsO Pipeline Watch: Alumis Initiates Phase 3 Clinical Program Evaluating Its Oral TYK2 Inhibitor in Moderate-to-Severe Plaque PsO
The Dermatology Digest
JULY 29, 2024
Alumis Inc. is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. This Phase 3 program consists of two identical 24-week global Phase 3 clinical trials (ONWARD1 and ONWARD2) designed to evaluate the efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis and includes a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of respo
Roflumilast Cream 0.15% for Atopic Dermatitis Now Commercially Available
Dermatology Times
JULY 29, 2024
Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.
Let's personalize your content